BL Pharmtech Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 02:58 am EST
Share
BL Pharmtech Corp. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 30,438.01 million compared to KRW 23,992.24 million a year ago. Net loss was KRW 2,123.04 million compared to KRW 517.96 million a year ago. Basic loss per share from continuing operations was KRW 24 compared to KRW 6 a year ago. Diluted loss per share from continuing operations was KRW 24 compared to KRW 6 a year ago. Basic loss per share was KRW 24 compared to KRW 6 a year ago.
For the nine months, sales was KRW 78,592.75 million compared to KRW 61,818.77 million a year ago. Net loss was KRW 7,346.19 million compared to KRW 5,691.74 million a year ago. Basic loss per share from continuing operations was KRW 83 compared to KRW 64 a year ago. Diluted loss per share from continuing operations was KRW 83 compared to KRW 64 a year ago. Basic loss per share was KRW 83 compared to KRW 64 a year ago.
BL PharmTech Corp, formerly Next BT Co Ltd, is a Korea-based company primarily engaged in the manufacture and sale of health foods. The Company operates its business through four segments. The Health Functional Food Business segment is engaged in the manufacture and sale of products such as red ginsengs, diet foods and vitamins. The Cosmetics Business segment is engaged in the manufacture and sale of anti-aging skincare products and, among others. The Diagnostic and Medical Business segment is engaged in the manufacture and sale of diagnostic kits and other products. The Other segment is engaged in the distribution of health foods and other products.
BL PHARMTECH CORP. 
